Find Delamanid manufacturers, exporters & distributors on PharmaCompass

Delamanid

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

7 API Suppliers, 7 Listed Suppliers, $ API Reference Price

7 API Suppliers
7 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 Europe

1 FDF Dossiers
1 Europe

DIGITAL CONTENT

8 NEWS #PharmaBuzz

media
8 NEWS #PharmaBuzz

MARKET PLACE

5 APIs

marketPlace
5 APIs

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 681492-22-8, Opc-67683, Delamanid (opc-67683), Opc 67683, (r)-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole, 8oot6m1pc7

Molecular Formula

C₂₅H₂₅F₃N₄O₆

Molecular Weight

534.5 g/mol

InChI Key

XDAOLTSRNUSPPH-XMMPIXPASA-N

FDA UNII

8OOT6M1PC7

Delamanid is a nitro-dihydro-imidazooxazole derivative, with antimycobacterial activity. Upon oral administration, delamanid, a prodrug, is activated via the mycobacterial F420 coenzyme system to form a reactive intermediate metabolite that inhibits the synthesis of the mycobacterial cell wall components methoxy-mycolic and keto-mycolic acid. This leads to the depletion of these cell wall components and destruction of mycobacteria.

1 2D Structure

Delamanid

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole

2.1.2 InChI

InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1

2.1.3 InChI Key

XDAOLTSRNUSPPH-XMMPIXPASA-N

2.1.4 Canonical SMILES

CC1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F

2.1.5 Isomeric SMILES

C[C@@]1(CN2C=C(N=C2O1)[N+](=O)[O-])COC3=CC=C(C=C3)N4CCC(CC4)OC5=CC=C(C=C5)OC(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

8OOT6M1PC7

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Opc-67683

2.3.2 Depositor-Supplied Synonyms

1. 681492-22-8

2. Opc-67683

3. Delamanid (opc-67683)

4. Opc 67683

5. (r)-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo[2,1-b]oxazole

6. 8oot6m1pc7

7. Mmv688262

8. Deltyba

9. (2r)-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1- Yl)phenoxy)methyl)-2,3-dihydroimidazo(2,1-b)oxazole

10. (2r)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole

11. Imidazo(2,1-b)oxazole, 2,3-dihydro-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)phenoxy)methyl)-, (2r)-

12. (2r)-2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]phenoxy]methyl]imidazo[2,1-b]oxazole

13. (2r)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole

14. (r)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole

15. Delamanid [usan]

16. Unii-8oot6m1pc7

17. (2r)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-3h-imidazo[2,1-b]oxazole

18. (r)-2-methyl-6-nitro-2-(4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole

19. Deltyba (tn)

20. Delamanid [inn]

21. Delamanid [jan]

22. Delamanid [mi]

23. Delamanid (jan/usan)

24. Delamanid [who-dd]

25. Opc-67683; Delamanid

26. Schembl57791

27. Delamanid [usan:inn:jan]

28. Chembl218650

29. Dtxsid60218326

30. Chebi:134742

31. Bcp07838

32. Ex-a2414

33. Mfcd18251539

34. Nsc794689

35. S5007

36. Zinc43100810

37. Akos025289781

38. Ccg-269934

39. Cs-5866

40. Db11637

41. Nsc-794689

42. Sb14863

43. Ncgc00348214-01

44. Ac-35849

45. As-56105

46. Delamanid; Opc 67683; Opc67683

47. Hy-10846

48. D09785

49. A856044

50. Q15408413

51. (2r)-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo(2,1-b)(1,3)oxazole

52. (2r)-2-methyl-6-nitro-2-[4-[4-[4-(trifluoromethoxy)phenoxy]piperidino]phenoxymethyl]-2,3-dihydroimidazo[2,1-b]oxazole

53. [(2r)-2-methyl-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidyl]phenoxy]methyl]-3h-imidazo[2,1-b]oxazol-6-yl]azinic Acid

54. 2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b]oxazole, (2r)-

2.4 Create Date

2006-04-29

3 Chemical and Physical Properties

Molecular Formula	C₂₅H₂₅F₃N₄O₆
Molecular Weight	534.5 g/mol
XLogP3	5.6
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	7
Exact Mass	534.17261902 g/mol
Monoisotopic Mass	534.17261902 g/mol
Topological Polar Surface Area	104 Å²
Heavy Atom Count	38
Formal Charge	0
Complexity	795
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 and 5. 1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

5 Pharmacology and Biochemistry

5.1 Pharmacology

The minimum inhibitory concentrations (MIC) of delamanid against _Mycobacterium tuberculosis_ isolates ranges from 0.006 to 0.024 g/mL. Among non-tuberculosis mycobacteria, delamanid has _in vitro_ activity against _M. kansasii_ and _M. bovis_. Delamanid has no in vitro activity against Gram negative or positive bacterial species and does not display cross-resistance to other anti-tuberculosis drugs. In murine models of chronic tuberculosis, the reduction of _M. tuberculosis_ colony counts by delamanid was demonstrated in a dose-dependent manner. Repeated dosing of delamanid may cause QTc-prolongation via inhibition of cardiac potassium channel (hERG channel), and this effect is mostly contributed by the main metabolite of delamanid, DM-6705. Animal studies indicate that delamanid may attenuate vitamin K-dependent blood clotting, increase prothrombin time (PT), and activated partial thromboplastin time (APTT).

5.2 ATC Code

J04AK06

J - Antiinfectives for systemic use

J04 - Antimycobacterials

J04A - Drugs for treatment of tuberculosis

J04AK - Other drugs for treatment of tuberculosis

J04AK06 - Delamanid

5.3 Absorption, Distribution and Excretion

Absorption

Following a single oral dose administration of 100 mg delamanid, the peak plasma concentration was 135 ng/mL. Steady-state concentration is reached after 10-14 days. Delamanid plasma exposure increases less than proportionally with increasing dose. In animal models (dog, rat, mouse), the oral bioavailability of delamanid was reported to be 35%60%. The absolute oral bioavailability in humans is estimated to range from 25 to 47%. Oral bioavailability in humans is enhanced when administered with a standard meal, by about 2.7 fold compared to fasting conditions because delamanid exhibits poor water solubility.

Route of Elimination

Delamanid is excreted primarily in the stool, with less than 5% excretion in the urine.

Volume of Distribution

The apparent volume of distribution (Vz/F) is 2,100 L. Pharmacokinetic data in animals have shown excretion of delamanid and/or its metabolites into breast milk. In lactating rats, the Cmax for delamanid in breast milk was 4-fold higher than that of the blood.

5.4 Metabolism/Metabolites

Delamanid predominantly undergoes metabolism by albumin and to a lesser extent, CYP3A4.. The metabolism of delamanid may also be mediated by hepatic CYP1A1, CYP2D6, and CYP2E1 to a lesser extent [31966]. Four major metabolites (M1M4) have been identified in plasma in patients receiving delamanid where M1 and M3 accounts for 13%18% of the total plasma exposure in humans. While they do not retain significant pharmacological activity, they may still contribute to QT prolongation. This is especially true for the main metabolite of delamanid, M1 (DM-6705). Delamanid is predominantly metabolized by serum albumin to form M1 (DM-6705) via hydrolytic cleavage of the 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole moiety. The formation of this major metabolite is suggested to be a crucial starting point in the metabolic pathway of delamanid. M1 (DM-6705) can be further catalyzed by three pathways. In the first metabolic pathway, DM-6705 undergoes hydroxylation of the oxazole moiety to form M2 ((4RS,5S)-DM-6720), followed by CYP3A4-mediated oxidation of hydroxyl group and tautomerization of oxazole to an imino-ketone metabolite, M3 ((S)-DM-6718). The second metabolic pathway involves the hydrolysis and deamination of the oxazole amine to form M4 (DM-6704) followed by hydroxylation to M6 ((4R,5S)-DM-6721) and M7 ((4S,5S)-DM-6722) and oxidation of oxazole to another ketone metabolite, M8 ((S)-DM-6717). The third pathway involves the hydrolytic cleavage of the oxazole ring to form M5 (DM-6706).

5.5 Biological Half-Life

The half life ranges from 30 to 38 hours.

5.6 Mechanism of Action

Delamanid is a prodrug that requires biotransformation via via the mycobacterial F420 coenzyme system, including the deazaflavin dependent nitroreductase (Rv3547), to mediate its antimycobacterial activity against both growing and nongrowing mycobacteria. Mutations in one of five coenzyme F420 genes, _fgd, Rv3547, fbiA, fbiB, and fbiC_ has been proposed as the mechanism of resistance to delamanid. Upon activation, the radical intermediate formed between delamanid and desnitro-imidazooxazole derivative is thought to mediate antimycobacterial actions via inhibition of methoxy-mycolic and keto-mycolic acid synthesis, leading to depletion of mycobacterial cell wall components and destruction of the mycobacteria. Nitroimidazooxazole derivative is thought to generate reactive nitrogen species, including nitrogen oxide (NO). However unlike isoniazid, delamanid does not alpha-mycolic acid.

API SUPPLIERS

01

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Contact Supplier

India

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

02

Hebi Xinhe Pharmaceutical

China

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

07

Hangzhou Longshine Bio-Tech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Omgene Life Sciences Pvt. Ltd

India

Duphat

Not Confirmed

Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Contact Supplier

India

Virtual Booth

Digital Content

Delamanid

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.

Portfolio PDF

Product Web Link

Virtual Booth

India

Duphat

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Import","activeIngredients":"DELAMANID","year":"2021","qtr":"Q2","strtotime":1621621800,"product":"DELAMANID SPRAY DRIED POWDER-DELTYBA DELAMANID SD POWDER","address":"1-1-151\/1, SAIRAM TOWERS, 4TH FLOORALEXANDER ROAD","city":"SECUNDERABAD, ANDHRA PRADESH","supplier":"OTSUKA NOVEL PRODUCTS ","supplierCountry":"JAPAN","foreign_port":"AMSTERDAM SCHIPHOL","customer":"VIATRIS","customerCountry":"INDIA","quantity":"149.86","actualQuantity":"149.856","unit":"KGS","unitRateFc":"2376","totalValueFC":"381347.6","currency":"USD","unitRateINR":"186402","date":"22-May-2021","totalValueINR":"27933460","totalValueInUsd":"381347.6","indian_port":"BOMBAY AIR","hs_no":"29280090","bill_no":"4035135","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AMSTERDAM SCHIPHOL","supplierAddress":"","customerAddress":"1-1-151\/1, SAIRAM TOWERS, 4TH FLOORALEXANDER ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1638469800,"product":"DELTYBA DELAMANID SD POWDER(COMMERCIAL POWDER SUPPLY)(DELAMANID SPRAY DRIED POWDER)","address":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,","city":"HYDERABAD,TELANGANA","supplier":"OTSUKA NOVEL PRODUCTS ","supplierCountry":"JAPAN","foreign_port":"N\/A","customer":"VIATRIS","customerCountry":"INDIA","quantity":"149.86","actualQuantity":"149.856","unit":"KGS","unitRateFc":"2376","totalValueFC":"392104.7","currency":"USD","unitRateINR":"197355.8","date":"03-Dec-2021","totalValueINR":"29574948.76","totalValueInUsd":"392104.7","indian_port":"BOMBAY AIR","hs_no":"29280090","bill_no":"6517108","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"","customerAddress":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648405800,"product":"DELTYBA DELAMANID SD POWDER(COMMERCIAL POWDER SUPPLY)(DELAMANID SPRAY DRIED POWDER 21.8 % (BULK)","address":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,","city":"HYDERABAD,TELANGANA","supplier":"OTSUKA NOVEL PRODUCTS ","supplierCountry":"JAPAN","foreign_port":"NA","customer":"VIATRIS","customerCountry":"INDIA","quantity":"194.80","actualQuantity":"194.802","unit":"KGS","unitRateFc":"2773.4","totalValueFC":"588235.2","currency":"USD","unitRateINR":"230156.8","date":"28-Mar-2022","totalValueINR":"44834999.32","totalValueInUsd":"588235.2","indian_port":"BOMBAY AIR","hs_no":"29280090","bill_no":"8049794","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

01 Otsuka Pharmaceutical

Japan

Duphat

Not Confirmed

02 Otsuka Pharmaceutical

Japan

Duphat

Not Confirmed

03 Bill & Melinda Gates Foundation

U.S.A

Duphat

Not Confirmed

04 Otsuka Pharmaceutical

Japan

Duphat

Not Confirmed

05 Otsuka Pharmaceutical

Japan

Duphat

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Delamanid Manufacturers

A Delamanid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Delamanid, including repackagers and relabelers. The FDA regulates Delamanid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Delamanid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Delamanid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Delamanid Suppliers

A Delamanid supplier is an individual or a company that provides Delamanid active pharmaceutical ingredient (API) or Delamanid finished formulations upon request. The Delamanid suppliers may include Delamanid API manufacturers, exporters, distributors and traders.

click here to find a list of Delamanid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Delamanid GMP

Delamanid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Delamanid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Delamanid GMP manufacturer or Delamanid GMP API supplier for your needs.

Delamanid CoA

A Delamanid CoA (Certificate of Analysis) is a formal document that attests to Delamanid's compliance with Delamanid specifications and serves as a tool for batch-level quality control.

Delamanid CoA mostly includes findings from lab analyses of a specific batch. For each Delamanid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Delamanid may be tested according to a variety of international standards, such as European Pharmacopoeia (Delamanid EP), Delamanid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Delamanid USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.

Market Place

Home

Post Enquiry

Market Place

Find Delamanid manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

7 API Suppliers

7 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers

1 Europe

DIGITAL CONTENT

8 NEWS #PharmaBuzz

MARKET PLACE

5 APIs

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 2,692

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

01

02

03

04

05

06

07

01

02

03

04

05

06

07

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

01

02

03

04

05

Delamanid Manufacturers

Delamanid Suppliers

Delamanid GMP

Delamanid CoA

What are you looking for?